LARGE B CELL LYMPHOMA—YEAR BY YEAR
Abstract
Non Hodgkin’s Lymphoma (NHL) comprises a group of lymphoproliferative disorders thefrequency of which continues to rise. Although many classification systems exist foridentifying specific histological subtypes, NHL is generally divided into indolent (low-grade)and aggressive (intermediate- and high-grade) forms. Large B Cell Lymphoma (LBCL) is oneof the commonest aggressive NHLs. The aim of this review is to provide a general overviewof NHL, its clinically practicable cellular classification, epidemiology and in depth overviewof the evolution of treatment of LBCL during the past 5 years. Current guidelines fromNational Cancer Institute (NCI), USA and National Institute on Clinical Excellence (NICE),UK are mentioned and recommendations according to our own set-up are suggested.Keywords: Non-Hodgkin’s Lymphoma, Large B Cell Lymphoma, RituximabReferences
Armitage JO: Treatment of non-Hodgkin's lymphoma. N Engl
J Med 1993;328(14):1023-30.
American Cancer Society. Cance r Facts and Figures 2006.
Atlanta: American Cancer Society;2006.
Coiffier B, Lepage E, Briere J , Herbrecht R, Tilly H,
Bouabdallah R et al. CHOP chemotherapy plus ritux imab
compared with CHOP alone in el derly patients with diffuse
large B-cell lymphoma. New Engl J Med. 2002;346:235-242.
Pfreundschuh MG, Trümper L, Ma D, Sterborg A, Pettengell
R, Trneny M et al. Randomized intergroup trial of first-line
treatment for patients =60 y ears with diffuse large B -cell
non-Hodgkin's lymph oma (DLBCL) with a CHOP -like
regimen with or without the an ti-CD20 antibody rituximabearly stopping after the first interim analysis. Proc Am Soc
Clin Oncol. 2004;23:556.
National Cancer Institute sponsored study of classifications of
non-Hodgkin's lymphomas: summary and description of a
working formulation for clinic al usage. The Non -Hodgkin's
Lymphoma Pathologic Classifica tion Project. Cancer
;49(10):2112-35.
Pugh WC. Is the working formul ation adequate for the
classification of the low grade lymphomas? Leuk Lymphoma
; 10(Suppl):1-8.
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML
et al. A revised European-American classification of lymphoid
neoplasms: a proposal from the International Lymphoma
Study Group. Blood 1994;84(5):1361-92.
Pittaluga S, Bijnens L, Teodor ovic I, Hagenbeek A,
Meerwaldt JH, Somers R, et al. Clinical analysis of 670 cases
in two trials of the European Organization for the Research
and Treatment of Cancer Lympho ma Cooperative Group
subtyped according to the Revise d European -American
Classification of Lymphoid Neoplasms: a comparison with the
Working Formulation. Blood 1996;87(10):4358-67.
Armitage JO, Weisenburger DD. New approach to classifying
non-Hodgkin's lymphomas: clinical features of the major
histologic subtypes. Non-Hodgkin's Lymphoma Classification
Project. J Clin Oncol 1998;16(8):2780-95.
A clinical evaluation of the I nternational Lymphoma Study
Group classification of non -Hodgkin's lymphoma. The Non -
Hodgkin's Lymphoma Classi fication Project. Blood
;89(11):3909-18.
Pileri SA, Milani M, Fraternali-Orcioni G, Sabattini E. From
the R.E.A.L. Classification to the upcoming WHO scheme: a
step toward universal categori zation of lymphoma entities?
Ann Oncol 1998;9(6):607-12.
Harris NL, Jaffe ES, Armitage JO. Lymphoma classification:
from R.E.A.L. to W.H.O. and beyond. Cancer: Principles and
Practice of Oncology Updates 1999;13(3):1-14.
Jaffe ES, Harris NL, Chan JKC. Proposed World Health
Organization Classification of Neoplastic Disease of
Hematopoietic and Lymphoid Tis sue. Am J Surg Pathol
;21(1):114-21.
Seow A, Lee J, Sng I, Fong CM, Lee HP. Non-Hodgkin's
lymphoma in an Asian population: 1968–1992 time trends and
ethnic differences in Singapore. Cancer 1996;77(9):1899.
Ries LAG, Kosary CL, Hankey BF . eds. SEER cancer
statistics review, 1973-1996. National Cancer Institute, 1999;
NIH publication No. 99-2789.
American Cancer Society. Cance r resource centre, non -
Hodgkin's lymphoma. www.cancer.org/cancerinfo (accessed
March 11).
Shipp MA, Mauch PM, Harris NL. Non -Hodgkin's
lymphomas. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds.
Cancer: principles and practic e of oncology. 5 th ed.
Philadelphia: Lippincott-Raven 1997:2165-217.
Lin AY, Tucker MA. Epidemiology of Hodgkin's disease and
non-Hodgkin's lymphoma. In: Canell os GP, Lister TA, Sk lar
JL, eds. The lymphomas. Philadelphia: Saunders; 1998:43-61.
Dinse GE, Umbach DM, Sasco AJ, Hoel DG, Davis DL.
Unexplained increases in cancer incidence in the United States
from 1975 to 1994: possible sentinel health indicators? Annu
Rev Public Health 1999;20:173.
Delves PJ, Roitt IM. The immune system. First of two parts. N
Engl J Med 2000;343(1):37.
Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer
SJ. BCL2 protein is topographica lly restricted in tissues
characterized by apoptotic cell death. Proc Natl Acad Sci USA
;88(16):6961.
Ehrlich P. On immunity with sp ecific reference to cell life.
Proc R Soc Lond Ser B. 1900; 66:424-48.
Köhler G, M ilstein C. Continuous cultures of fused cells
secreting antibody of predefin ed specificity. Nature.
;256:495-7.
Multani PS, Grossbard ML. Mono clonal antibody -based
therapies for haematologic mal ignancies. J Clin Oncol.
;16:3691-710.
Leget GA, Czuczman MS. Use of rituximab, the new FDAapproved antibody. Curr Opin Oncol. 1998;10:548-51.
Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE,
Raab R, et al. Depletion of B cells in vivo by a chimeric
mouse human monoclonal antibod y to CD20. Blood
;83:435-45.
Maloney DG, Press OW. Newer treatments for non-Hodgkin's
lymphoma: monoclonal antibodie s. Oncology. 1998 (suppl
:63-76.
Maloney DG. Unconjugated monoclonal antibody therapy of
lymphoma. In: Grossbard ML, ed. Monoclonal antibody-based
therapy of cancer. New York: Dekker; 1998:53-79.
Glennie MJ. Overview of monocl onal antibody-based targets
for antibody therapy of lympho ma. In: Biological therapy of
lymphoma. Baylor -Simmons Cancer Centre. Data fr om:
Barclay AN, Brown MH, Law SKA. The leukocyte antigen
facts book. 2nd ed. London: Academic Press;1997:3.
Anderson KC, Bates MP, Slaughe nhoupt BL, Pinkus GS,
Schlossman SF, Nadler LM. Expr ession of human B cell -
associated antigens on leukaemias and lymphomas: a model of
human B cell differentiation. Blood. 1984;63:1424-33.
Longo DL, DeVita VT Jr, Jaffe ES. Lymphocytic lymphomas.
In: DeVita VT Jr, Hellman S, R osenberg SA, eds. Cancer:
principles and practice of oncology. 4th e d. Philadelphia:
Lippincott; 1993:1859-927.
Maloney DG, Grillo-López AJ, Bodkin DJ, White CA, Liles
TM, Royston I et al. IDEC-C2B8 (rituximab) anti -CD20
monoclonal antibody therapy in patients with relapsed low -
grade non-Hodgkin's lymphoma. Blood. 1997;90:2188-95.
McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman
MS, Williams ME et al. Rituximab chimeric anti -CD20
monoclonal antibody therapy for relapsed indolent lymphoma:
J Ayub Med Coll Abbottabad;19(4)
half of patients respond to a four-dose treatment program. J
Clin Oncol. 1998; 16:2825-33.
Davis TA, White CA, Grillo -López AJ, Velásquez WS, Link
B, Maloney DG et al. Single-agent monoclonal antibody
efficacy in bulky non-Hodgkin's lymphoma: results of a Phase
II trial of rituximab. J Clin Oncol. 1999;17:1851-7.
Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM,
Grogan TM et al. Chemotherapy alone compared with
chemotherapy plus radiotherapy for localized intermediate -
and high-grade non-Hodgkin's lymphoma. N Engl J M ed
;339:21.
Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et
al. Rituximab (anti -CD20 monoclonal antibody) for the
treatment of patients with rel apsing or refractory aggressiv e
lymphoma: a multi -centre Phase II study. Blood.
;92:1927-32.
Vose JM, Link BK, Grossbard ML , Czuczman M, Grillo -
Lopez A, Fisher RI. Long-term update of a phase II stud y of
rituximab in combination with CHOP chemotherapy in
patients with previously untreated, aggressive non-Hodgkin's
lymphoma. Leuk Lymphoma. 2005 Nov;46(11):1569-73.
Maloney DG, Smith B, Appelbaum FR. The antitumor effect
of monoclonal anti -CD20 antibody therapy includes direct
anti-proliferative activity and induction of apoptosis in CD20
positive non -Hodgkin's lymphoma cell lines. B lood.
;88:637. Abstract.
Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida
B.. Chimeric anti-CD20 (IDEC-C2B8) monoclonal anti-body
sensitizes a B cell lymphoma cell line to cell killing by
cytotoxic drugs. Cancer Biother. 1997;12:177-86.
Czuczman M, Grillo-Lopez AJ, White CA. Rituximab/CHOP
chemoimmunotherapy in patients with low grade lymphoma
(LG/F NHL): progression free s urvivals (PFS) after three
years (median) follow-up. Blood. 1999:94.Abstract 432.
Coiffier B, Lepage E, Briere J , Herbrecht R, Tilly H,
Bouabdallah R et al. CHOP chemotherapy plus ritux imab
compared with CHOP alone in el derly patients with diffuse
large B-cell lymphoma. New Engl J Med. 2002;346:235-42.
Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K,
Klasa R, et al. Introduction of combined CHO P-rituximab
therapy dramatically improved outcome of diffuse large-B-cell
lymphoma (DLBC) in British Col umbia (BC). Blood
;102:29a Abstract 88.
Miller TP, Unger JM, Spier C, Stea B, Cantu E, LeBlanc M et
al. Effect of adding rituximab t o three cycles of CHOP plus
involved-field radiotherapy for limited-stage aggressive diffuse
B-cell lymphoma (SWOG-0014). Blood. 2004;104:49a.
National Institute of Clinical Excellence. Technology
Appraisal 65, Rituximab for ag gressive non -Hodgkin’s
lymphoma. www.nice.org.uk. (Accessed 21 March 2006)
National Cancer Institute. Tre atment of Common Cancers.
Non-Hodgkin’s Lymphoma. http://nci.nih.gov/cancertopics/
pdq/treatment/adult-non-hodgkins/healthprofessional.
(Accessed 21 March 2006)
Issue
Section
License
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
